Sarepta Therapeutics, Inc. et al. vs. Genzyme Corporation et al.

Explore the PTAB proceeding IPR2026-00270 filed by Sarepta Therapeutics, Inc. et al. on 2026-02-26. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2026-00270

Filing Date

2026-02-26

Accorded Filing Date

2026-02-26

Institution Decision Date

2026-07-21

Last Modified Date

2026-08-21

Proceeding Type

IPR

Termination Date

2026-07-21

Trial Status

Institution Denied

Parties & Counsel

Petitioner

Sarepta Therapeutics, Inc. et al.

Represented By

Wilson, Robertet al

Patent Owner / Respondent

Genzyme Corporation et al.

Represented By

Antons, Amandaet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1700 - Chemical & Materials Engineering

Patent Information

1 Patent Involved

Respondent Application Number 19013863

Respondent Patent Number 12298313

External Links

Espacenet

Google Patents

Respondent Inventor Xiaoying JIN et al

Respondent Tech Center TC 1700 - Chemical & Materials Engineering

Address and Attorney/Agent Information

58 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name Sanofi/Genzyme c/o Morrison & Foerster LLP

Customer Number 89300

Address 755 Page Mill Road, Palo Alto, CA, 94304, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
36844	Joseph Kirk Jr	908-981-6911
39150	John Conway	908-981-6688
39156	B Creagan	617-685-5660
39933	Robert Cerpa	650-813-5715
40130	Catherine Polizzi	650-813-5651
40564	Anne Collins	978-341-0036
42198	Edna Vassilovski	857-331-2474
43743	Jeffrey Lee	617-610-9638
44045	Sandra Brockman-Lee	857-523-9199
45736	Pamela Torpey	508--27-1-0683
45979	Milan Vinnola	619-238-0062
52285	Shannon Reaney	650-813-5600
52395	Jie Zhou	650-813-5922
52610	Kelly Bender	2485930581
52916	Gojeb Frehywot	617-685-5666
54154	Allyson Hatton	508-361-7392
54958	Janann Ali	617-685-5645
59682	Jeremy Bond	617-685-5653
60243	Seth Snyder	212-698-3500
61358	Ryan Mcquade	617-838-5595
63001	Stephanie Donahue	908-331-4406
63750	Mayssam Ali	617-685-5646
63950	Jillian Pesin-Fulop	617-648-4772
64259	Xuemei Peng	908-981-6951
64740	Alan Townsley	202-857-2278
64828	Jeffrey Weber	617-685-6431
67265	Yi Wang	617-685-5735
67946	Nicholas Bero	585-305-7782
68315	Meenakshy Chakravorty	781-418-9211
69080	Lisa Silverman	650-813-5735
70339	John Chapman	650-813-5726
70740	Erika Wallace	617-937-1397
71226	Meghan Klaric	313-465-7211
71792	Anita Choi	415-268-6445
72475	Indrani Dasgupta	617-685-5977
73237	Qiwen Zhong	858-314-5431
73248	Meghan Poon	650-813-4108
73258	Ethan Weiner	650-813-4119
73475	Kevin Jones	415-268-7483
74124	Evan King	781-234-4286
76847	Courtney Cronin	312-701-8755
79382	Kelsey Roberts Kingman	650-889-0114
79763	Sarah Bloch	415-268-6423
800111	Xinhui Zhang	213-892-5601
80029	Thomas Keane	617-368-0502
80264	Christopher Marion	314-517-7022
80424	Victoria Pedanou	508-736-4409
80495	Paige Smith	617-648-4763
80633	Thomas Dawson	617-648-4718
80779	Martin Ellinger	858-314-7615
80994	Briana Mittleman	913-522-0582
81228	Adrienne Cohen	415-268-6854
81337	Deborah Pohlmann	857-234-5168
81386	Erin May	617-251-9709
81412	Emily Roberts	141-523-18674
82515	Elizabeth Cooke	161-764-84804
82697	Keunbong Do	415-268-7536
82998	Yocelyn Recinos	646-712-4790

Proceeding Documents

100

Institution Decision: Deny DECISION

2026-07-21 FILING PARTY: BOARD

Download

Director Discretionary Decision: Refer RESPONSE

2026-07-14 FILING PARTY: BOARD

Download

Patent Owner's Updated Mandatory Notices NOTICE

2026-06-08 FILING PARTY: PATENT OWNER

Download

1045

Ex. 1045 Exhibit

2026-06-05 FILING PARTY: PETITIONER

Download

1047

Ex. 1047 Exhibit

2026-06-05 FILING PARTY: PETITIONER

Download

Sarepta Therapeutics, Inc. et al. vs. Genzyme Corporation et al.

Proceeding Overview

Parties & Counsel

Petitioner

Sarepta Therapeutics, Inc. et al.

Represented By

Patent Owner / Respondent

Genzyme Corporation et al.

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Institution Decision: Deny DECISION

Director Discretionary Decision: Refer RESPONSE

Patent Owner's Updated Mandatory Notices NOTICE

Ex. 1045 Exhibit

Ex. 1047 Exhibit

Ex. 1049 Exhibit

Ex. 1042 Exhibit

Ex. 1044 Exhibit

Ex. 1050 Exhibit

Ex. 1048 Exhibit

Ex. 1046 Exhibit

Petitioner's Opposition to Discretionary Denial Brief RESPONSE

Ex. 1041 Exhibit

Ex. 1043 Exhibit

Knolhoff, Callahan, and Croley, “Mass Accuracy and Isotopic Abundance Measurements for HR-MS Instrumentation: Capabilities for Non-Targeted Analyses,” Exhibit

Patent Owner's Preliminary Response POPR

Wright & Wright, “Advances in LC: Bioanalytical Method Transfer,” Exhibit

Declaration of John A. McLean, Ph.D. Exhibit

Kontogiannis et al., “Characterization of AAV vectors: A review of analytical techniques and critical quality attributes,” Exhibit

Supplemental Materials to Ansong et al., “Top-down proteomics reveals a unique protein S-thiolation switch in Salmonella Typhimurium in response to infection-like conditions,” Exhibit

Lancaster and Ha et al., “Characterization of N-glycosylation profiles from mammalian and insect derived chikungunya VLP,” Exhibit

Salganik et al., “Evidence for pH-Dependent Protease Activity in the Adeno-Associated Virus Capsid,” Exhibit

Wörner and Heck et al., “Adeno-associated virus capsid assembly is divergent and stochastic,” Exhibit

Curriculum Vitae of John A. McLean, Ph.D. Exhibit

ICH Harmonised Tripartite Guideline: Validation of Analytical Procedures: Text and Methodology Q2(R1) Exhibit

May & McLean, “Advanced Multidimensional Separations in Mass Spectrometry: Navigating the Big Data Deluge,” Exhibit

Boys et al., “Protein Oxidative Modifications During Electrospray Ionization: Solution Phase Electrochemistry or Corona Discharge-Induced Radical Attack?,” Exhibit

Han, Aslanian, & Yates, “Mass spectrometry for proteomics,” Exhibit

Valeja et al., “Three Dimensional Liquid Chromatography Coupling IEC/HIC/RPC for Effective Protein Separation in Top-Down Proteomics,” Exhibit

Patent Owner's Request for Discretionary Denial RESPONSE

Vliet Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 87 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 110 Exhibit

US Patent 11,698,377 File History Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 83 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) - Defendant’s Supplemental Initial Invalidity Contentions Exhibit

US Patent 11,698,377 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 37 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 99 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 68 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 78 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 102 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 59 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 92 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 45 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 67 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 76 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 35 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 28 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 91 Exhibit

Bark Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 162 Exhibit

Petitioner's Sotera Stipulation OTHER

Declaration of Katherine Helm Exhibit

Notice of Intent to Designate Katherine Helm as Back-Up Counsel NOTICE

Notice: Mandatory Notice NOTICE

Notice: Power of Attorney NOTICE

Notice: NOTICE OF FILING DATE ACCORDED TO PETITION AND TIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE NOTICE

Ex. 1024 Exhibit

Ex. 1022 Exhibit

Ex. 1013 Exhibit

Ex. 1014 Exhibit

Ex. 1039 Exhibit

Notice: Power of Attorney NOTICE

Ex. 1001 Exhibit